当前位置:
X-MOL 学术
›
Cancer Discov.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Gemtuzumab Ozogamicin Makes a Comeback
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-09-20 , DOI: 10.1158/2159-8290.cd-nb2017-132 American Association for Cancer Research
中文翻译:
Gemtuzumab Ozogamicin卷土重来
更新日期:2017-09-20
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-09-20 , DOI: 10.1158/2159-8290.cd-nb2017-132 American Association for Cancer Research
After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed/refractory disease. The CD33-targeting antibody–drug conjugate can be given as a single agent or in combination with chemotherapy.
中文翻译:
Gemtuzumab Ozogamicin卷土重来
吉妥单抗ozogamicin在7年前被撤出市场后,已获得FDA的重新批准,这次是针对新诊断为急性髓性白血病的成年人以及2岁及以上复发/难治性疾病的患者。靶向CD33的抗体-药物偶联物可以单药或与化学疗法联用。